<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646902</url>
  </required_header>
  <id_info>
    <org_study_id>Kyntosa_02_20200428</org_study_id>
    <secondary_id>PTDC/MED-TOX30418/2017</secondary_id>
    <nct_id>NCT04646902</nct_id>
  </id_info>
  <brief_title>Kynurenine/Tryptophan Ratio in Hypertension Associated to Obstructive Sleep Apnea</brief_title>
  <acronym>KYNTOSA</acronym>
  <official_title>Relevance of the Ratio Kynurenine/Tryptophan to Characterize Hypertension Associated to Obstructive Sleep Apnea (KYNTOSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Nova de Lisboa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro Hospitalar Lisboa Ocidental</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar de Lisboa Central</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Beatriz Ângelo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Fernando Fonseca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital da Luz, Portugal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Nova de Lisboa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive Sleep Apnea (OSA) is an independent risk factor for hypertension (HTN) and the&#xD;
      most common cause of resistant HTN. The mechanisms underlying OSA-associated HTN are not&#xD;
      completely understood. This is crucial to find novel therapeutic targets of OSA-associated&#xD;
      HTN. The Aryl Hydrocarbon Receptor (AHR) is a cytosolic transcription factor that has been&#xD;
      linked with the pathogenesis of HTN.&#xD;
&#xD;
      This study aims to evaluate the role of endogenous ligands of AHR such as kynurenine in&#xD;
      discriminating patients with OSA-associated HTN. For that aim, a case-control study will be&#xD;
      performed in patients with and without hypertension exposed and not exposed to OSA.&#xD;
      Kynurenine and other metabolites will be quantified in urine and serum samples.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">December 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Kynurenine / Tryptophan ratio</measure>
    <time_frame>Day 1 (visit 1)</time_frame>
    <description>Ratio between kynurenine and tryptophan concentrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of metabolites</measure>
    <time_frame>Day 1 (visit 1)</time_frame>
    <description>The relevant metabolites and their concentration will be identified by Partial Least Square Discriminant Analysis (PLS-DA) applied to non-targeted metabolomics.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">906</enrollment>
  <condition>Hypertension Secondary</condition>
  <arm_group>
    <arm_group_label>HTN_OSA</arm_group_label>
    <description>Patients with hypertension* with obstructive sleep apnea**&#xD;
* Hypertension will be defined as: i) use of antihypertensive drug(s) and stable dose for at least 2 weeks prior to inclusion; or ii) in untreated patients: office systolic blood pressure values &gt;= 140 mmHg and/ or diastolic blood pressure values &gt;= 90 mmHg.&#xD;
** OSA will be defined with a polysomnography level 1, 2 or 3 performed within the previous twelve months with:&#xD;
an apnea-hypopnea index &gt; 5 events per hour (with more than 50% of obstructive events) associated with symptoms (associated sleepiness, fatigue, insomnia, snoring, subjective nocturnal respiratory disturbance or observed apnea) or medical/psychiatric disorder (hypertension, coronary artery disease, atrial fibrillation, congestive heart failure, stroke, diabetes, cognitive dysfunction, or mood disorder), OR&#xD;
an apnea-hypopnea index &gt; 15 events per hour, AND&#xD;
no significant changes in health, medications, or lifestyle since the polysomnography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HTN_NoOSA</arm_group_label>
    <description>Patients with hypertension without obstructive sleep apnea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NoHTN_OSA</arm_group_label>
    <description>Patients without hypertension with obstructive sleep apnea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NoHTN_NoOSA</arm_group_label>
    <description>Patients without hypertension without obstructive sleep apnea (healthy controls)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples Urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include 4 groups of adults: healthy volunteers; normotensive OSA&#xD;
        patients; hypertensive OSA patients; hypertensive non OSA patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        CASES (subjects with hypertension with and without OSA)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥ 30 years old attending the outpatient clinics of the clinical sites.&#xD;
&#xD;
          -  Diagnosis of hypertension defined either as: a) use of antihypertensive drug(s) and&#xD;
             stable dose for at least 2 weeks prior to inclusion; or b) in untreated patients:&#xD;
             office systolic blood pressure values &gt;= 140 mmHg and/ or diastolic blood pressure&#xD;
             values &gt;= 90 mmHg.&#xD;
&#xD;
          -  Able to understand and communicate effectively with study personnel.&#xD;
&#xD;
          -  Giving written informed consent to participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Self-reported pregnancy or breastfeeding.&#xD;
&#xD;
          -  Patients on haemodialysis or peritoneal dialysis.&#xD;
&#xD;
          -  Chronic liver disease with Child-Pugh score B or higher.&#xD;
&#xD;
          -  Hypertension attributed to renal artery stenosis, primary hyperaldosteronism,&#xD;
             pheochromocytoma, Cushing's syndrome, coarctation of aorta.&#xD;
&#xD;
          -  History of any OSA surgical treatment to the palatal and hypopharyngeal regions,&#xD;
             notably uvulopalatopharyngoplasty surgery (UPPP), palatal radio frequency ablation,&#xD;
             tonsillectomy, lingual tonsillectomy, partial glossectomy, tongue base radio frequency&#xD;
             ablation, genioglossal advancement, hyoid suspension, maxillomandibular advancement&#xD;
             surgery (MMA) and active use of hypoglossal nerve stimulator.&#xD;
&#xD;
          -  Patients with a good adherence to CPAP, defined as the use of CPAP for at least 4&#xD;
             hours/night on 70% of nights during the last 3 months.&#xD;
&#xD;
          -  Pulmonary hypertension.&#xD;
&#xD;
          -  Current diagnosed oncological disease.&#xD;
&#xD;
          -  Patients with known chronic or acute infectious diseases.&#xD;
&#xD;
          -  Other current severe progressive or uncontrolled disease which in the judgement of the&#xD;
             investigator renders the patient unsuitable for the study&#xD;
&#xD;
        CONTROLS (individuals without hypertension with and without OSA) For each case, an age and&#xD;
        gender-matched control will be selected.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Patients on haemodialysis or peritoneal dialysis.&#xD;
&#xD;
          -  Chronic liver disease with Child-Pugh score b or higher.&#xD;
&#xD;
          -  History of any OSA surgical treatment to the palatal and hypopharyngeal regions,&#xD;
             notably uvulopalatopharyngoplasty surgery (UPPP), palatal radio frequency ablation,&#xD;
             tonsillectomy, lingual tonsillectomy, partial glossectomy, tongue base radio frequency&#xD;
             ablation, genioglossal advancement, hyoid suspension, maxillomandibular advancement&#xD;
             surgery (MMA) and active use of hypoglossal nerve stimulator.&#xD;
&#xD;
          -  Patients with a good adherence to CPAP, defined as the use of CPAP for at least 4&#xD;
             hours/night on 70% of nights during the last 3 months.&#xD;
&#xD;
          -  Pulmonary hypertension.&#xD;
&#xD;
          -  Current diagnosed oncological disease.&#xD;
&#xD;
          -  Patients with known chronic or acute infectious diseases.&#xD;
&#xD;
          -  Patients with known chronic or acute infectious diseases.&#xD;
&#xD;
          -  Other current severe progressive or uncontrolled disease which in the judgement of the&#xD;
             investigator renders the patient unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria E Monteiro, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade NOVA Lisboa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria E Monteiro, PhD</last_name>
    <phone>+351 218803000</phone>
    <phone_ext>26008</phone_ext>
    <email>emilia.monteiro@nms.unl.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judit Morello, PhD</last_name>
    <phone>+351 218803000</phone>
    <phone_ext>26013</phone_ext>
    <email>judit.morello@nms.unl.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital da Luz</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anabela Raimundo</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>tryptophan</keyword>
  <keyword>aryl hydrocarbon receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

